Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar: financing pressure. About 2.7 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), an at-the-market (ATM) program filed Oct 21, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 months of cash or less, 51% sold new shares within three months and 73% were lower 60 trading days later (median -24%). How we know
$2.6MCash on Hand
2.7mo Cash Runway
3.3%Short Interest
$6Analyst Target (2)
Follow NNVC by emailGet an email when NNVC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NNVC, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 21, 2026 ·
Financing NanoViricides amended its at-the-market offering prospectus supplement, raising the maximum amount it may sell through D. Boral Capital LLC to $2,374,774 of common stock, due to a public float limit under Form S-3. Form 424B5 · SEC filing
Oct 8, 2026 ·
Shareholder vote Board recommends voting FOR all proposals at the November 21, 2026 annual meeting: re-electing Todd E. Rokita as a Class I director and Makarand Jawadekar and Brian Zucker as Class II directors, and ratifying EisnerAmper, LLP as independent accountant for fiscal 2027. Form DEF 14A · SEC filing
Sep 29, 2026 ·
Leadership NanoViricides extended employment agreements for President Anil Diwan and CFO Meeta Vyas through June 30, 2027. Diwan's salary is $400,000, and he received 10,204 Series A Preferred shares vesting quarterly. Form 8-K · SEC filing
Sep 28, 2026 ·
Annual report for the period ended Jun 30, 2026 Form 10-K · SEC filing
Sep 3, 2026 ·
Financing Prospectus for resale of 2,516,339 shares issuable on exercise of common warrants at $1.75, issued in a July 24, 2026 registered direct offering. The company receives no proceeds from resales but could receive about $4.4 million if the warrants are exercised in full. Form 424B3 · SEC filing
Aug 21, 2026 ·
Financing Registers resale by a selling stockholder of up to 2,516,339 shares of common stock issuable on exercise of common warrants at $1.75 per share, from a July 24, 2026 registered direct offering. The company receives no proceeds from the resale but would get about $4.4 million if the warrants are exercised in full. Form S-3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
NNVC holds $2.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.9M/quarter from operations,
an estimated runway of 2.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:69 · High
Cash runway 3 months +40
ATM program on file since Oct 2026 +15
Shelf registration (S-3, Jun 2026) +10
Share count +46% in a year +14
Raised after last reported balance sheet (Jul 2026) -10
Share count 25,525,000 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full NNVC picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NNVC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.